Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia

Vicenç Falcó, Joaquin Burgos, Elisabeth Papiol, Ricard Ferrer, Benito Almirante

Research output: Contribution to journalReview articleResearchpeer-review

8 Citations (Scopus)


© 2016 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Hospital acquired pneumonia (HAP) is one of the main infections acquired by patients during a stay in hospital. The main issue when dealing with patients with HAP and ventilator associated pneumonia (VAP) is the increasing role of multi-drug resistant organisms (MDROs). Areas covered: In this review the authors summarize the actual situation of MDROs as a cause of HAP and VAP. They also review the current treatment options stated in the most important international guidelines. Finally, they focus on the investigational drugs that have reached the phase III stage of development and the novel compounds that are being studied in phase I and II clinical trials. Expert opinion: Thanks to their excellent activity against MDROs, drugs in development for the treatment of HAP and VAP can significantly improve the therapeutic options available. In selected patiesnts, the possibility to administer directed therapy with monoclonal antibodies to specific pathogens is an exciting strategy in the fight against widespread resistance.
Original languageEnglish
Pages (from-to)653-665
JournalExpert Opinion on Investigational Drugs
Issue number6
Publication statusPublished - 2 Jun 2016


  • Ceftazidime/avibactam
  • ceftolozane/tazobactam
  • hospital acquired pneumonia
  • imipenem/relevactam
  • multidrug resistant microorganisms
  • plazomicin
  • tedizolid


Dive into the research topics of 'Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia'. Together they form a unique fingerprint.

Cite this